68Ga-PSMA-11

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

Prostate CarcinomaProstatic NeoplasmsMetastatic Castration-Resistant Prostate Cancer, Mcrpc

56 competitors in Prostate Carcinoma

#DrugCompanyPhaseTrials

1

Erleada

Johnson & Johnson

Approved

22

Nubeqa

Bayer

Approved

13

Farxiga

AstraZeneca

Approved

—4

Zometa

Pfizer

Approved

—5

Lynparza

AstraZeneca

Approved

—6

Lupron

AbbVie

Approved

—7

Balversa

Johnson & Johnson

Approved

—8

Estrace

Novo Nordisk

Approved

—9

Xtandi

Astellas

Approved

—10

Ritalin

Novartis

Approved

—Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial

An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.

Active, not recruiting·Novartis·Phase 2·NCT06004661·23 enrolled

Prostatic Neoplasms1 trial

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer

Active, not recruiting·Novartis·Phase 3·NCT04689828·469 enrolled

Prostate Carcinoma1 trial

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT07674771·30 enrolled

Details

Drug Info

Related News